SIS
RVNC

Strategic Investment Solutions’s Revance Therapeutics, Inc. RVNC Stock Holding History

Strategic Investment Solutions’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$879 – 693
2024
Q4 		$879 Hold
100
– – ﹤0.01% 567
2024
Q3 		$519 Hold
100
– – ﹤0.01% 569
2024
Q2 		$378 Buy
+100
New +$341 ﹤0.01% 567
2023
Q4 		$1.32K Sell
150
-3,000
-95% -$24.6K ﹤0.01% 990
2023
Q3 		$60.6K Buy
3,150
+3,100
+6,200% +$59.6K ﹤0.01% 599
2023
Q2 		$1.18K Sell
50
-50
-50% -$1.56K ﹤0.01% 783
2023
Q1 		$3.22K Buy
+100
New +$3.12K ﹤0.01% 815

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Strategic Investment Solutions's RVNC Position: Q1 2025 in Review

Strategic Investment Solutions sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 100 shares — an estimated $879 sold.

Strategic Investment Solutions first reported a position in RVNC in Q1 2023 and held it in 7 quarters. The position peaked at $60.6K in Q3 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Strategic Investment Solutions reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Strategic Investment Solutions sold 100 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $879.
  • Strategic Investment Solutions first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 7 quarters.
  • Strategic Investment Solutions's Revance Therapeutics, Inc. position peaked at $60.6K in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Strategic Investment Solutions's 13F filing for Q1 2025, filed 9 May 2025.